Mehta Formulations Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 21-12-2024
- Paid Up Capital ₹ 0.97 M
as on 21-12-2024
- Company Age 27 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.21 Cr
as on 21-12-2024
- Satisfied Charges ₹ 3.15 Cr
as on 21-12-2024
- Revenue 10.22%
(FY 2017)
- Profit 109.82%
(FY 2017)
- Ebitda -5.92%
(FY 2017)
- Net Worth 9.48%
(FY 2017)
- Total Assets 5.97%
(FY 2017)
About Mehta Formulations
The Company is engaged in the Real Estate And Construction Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.97 M.
The company currently has active open charges totaling ₹8.21 Cr. The company has closed loans amounting to ₹3.15 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rakesh Mehta and Mona Kamdar serve as directors at the Company.
- CIN/LLPIN
U24231WB1997PTC086053
- Company No.
086053
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Dec 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mehta Formulations?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Mehta  | Director | 08-Dec-1997 | Current |
| Mona Kamdar | Director | 08-Dec-1997 | Current |
Financial Performance of Mehta Formulations.
Mehta Formulations Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 10.22% increase. The company also saw a substantial improvement in profitability, with a 109.82% increase in profit. The company's net worth moved up by a moderate rise of 9.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mehta Formulations?
In 2017, Mehta Formulations had a promoter holding of 100.00%. The company had 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Exim Distributors Private LimitedActive 24 years 5 months
Rakesh Mehta and Mona Kamdar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 14 Mar 2016 | ₹8.21 Cr | Open |
Bank Of Baroda Creation Date: 03 Oct 2002 | ₹3.15 Cr | Satisfied |
How Many Employees Work at Mehta Formulations?
Unlock and access historical data on people associated with Mehta Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mehta Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mehta Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
